公开(公告)号：US09446043B2

公开(公告)日：2016-09-20

申请号：US14647939

申请日：2013-11-26

Applicant: Novartis AG

Inventor： Dale Porter ,  Caroline Emery ,  Lujian Tan ,  Padmaja Yerramilli-Rao

IPC: A61K31/517 ,  A61K31/496 ,  A61K31/4184 ,  A61K31/4025 ,  A61K31/404 ,  A61K45/06 ,  A61K31/506

CPC classification number: A61K31/517 ,  A61K31/4025 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/496 ,  A61K31/506 ,  A61K45/06 ,  A61K2300/00

Abstract: A pharmaceutical combination comprising (a) a protein kinase C (PKC) inhibitor compound, or a pharmaceutically acceptable salt thereof, and (b) at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Abstract translation: 一种药物组合，其包含（a）蛋白激酶C（PKC）抑制剂化合物或其药学上可接受的盐，和（b）至少一种丝裂原活化蛋白激酶（MEK）抑制剂或其药学上可接受的盐，以及任选的药学上可接受的盐 载体，用于同时，分开或顺次施用; 这种组合在增殖性疾病治疗中的应用; 以及治疗患有增殖性疾病的受试者的方法，包括施用治疗有效量的这种组合。